<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040351</url>
  </required_header>
  <id_info>
    <org_study_id>hydrosalpinx1</org_study_id>
    <nct_id>NCT01040351</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Aspiration of Hydrosalpingeal Fluid and IVF-ET Outcomes</brief_title>
  <official_title>Effect of Ultrasound Guided Aspiration of Hydrosalpingeal Fluid at the Time of Oocyte Retrieval on the Outcomes of IVF-ET, a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ahmed Elgazzar Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the ultrasound guided aspiration of
      hydrosalpingeal fluid at the time of oocyte retrieval can improve the outcomes of IVF-ET .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Cochrane review of prospective randomized trials of laparoscopic salpingectomy confirmed
      the beneficial effect of laparoscopic salpingectomy on IVF ET outcomes in patients with
      hydrosalpinges. Surgery is not usually safe especially in patients with extensive adhesions,
      morbid obesity and previous multiple laparotomies. Other less invasive options for patients
      with hydrosalpinges as ultrasound guided aspiration of hydrosalpingeal fluid, antibiotics and
      hysteroscopic occlusion of fallopian tube were studied in order to find an alternative to
      salpingectomy. Although these methods are simple and getting popular,current data are
      inadequate to recommend these treatment options instead of salpingectomy. The aim of this
      study is to determine whether the ultrasound guided aspiration of hydrosalpingeal fluid at
      the time of oocyte retrieval can improve the outcomes of IVF-ET .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Who Achieved Clinical Pregnancy in a Transfer Cycle</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
    <description>The Number of Participants Who Achieved Clinical Pregnancy( presence of intrauterine gestational sac detected by transvaginal ultrasound
)in a transfer cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Achieved Ongoing Pregnancy in a Transfer Cycle .</measure>
    <time_frame>18 weeks after embryo transfer</time_frame>
    <description>The number of participants who Achieved Ongoing pregnancy (pregnancy for more than 18 weeks after embryo transfer) in a transfer cycle .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>1: Hydrosalpinx needle aspiration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. no aspiration</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>IVF-ET is done without prior aspiration of hydrosalpingeal fluid</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound guided aspiration of hydrosalpingeal fluid</intervention_name>
    <description>Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.</description>
    <arm_group_label>1: Hydrosalpinx needle aspiration</arm_group_label>
    <other_name>ultrasound guided Hydrosalpinx needle aspiration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unilateral or bilateral hydrosalpinges visible by ultrasound

          -  Age between 18 - 37 years

          -  Period of infertility &gt; 1 year

          -  Body mass index between 19-29

          -  Normal basal luteinizing hormone (LH), follicle stimulating hormone (FSH) and
             prolactin concentrations

          -  Normal recent semen analysis (according to World Health Organization criteria)

        Exclusion Criteria:

          -  Uterine fibroid requiring surgical removal

          -  Endometriosis

          -  Male factor of infertility requiring ICSI

          -  Previous IVF cycles

          -  History of recurrent miscarriage

          -  Endocrinologic disorders

          -  Presence of systemic disease contraindicating pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usama M Fouda, M.D, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lecturer of obstetrics and Gynecology , Faculty of medicine ,Cairo university.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M sayed, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant professor of obstetrics and Gynecology , Faculty of medicine ,Cairo university.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmed Elgazzar hospital , Assisted conception unit</name>
      <address>
        <city>Giza</city>
        <state>35 Eleshreen st. King Faisal.</state>
        <zip>12111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Hammadieh N, Coomarasamy A, Ola B, Papaioannou S, Afnan M, Sharif K. Ultrasound-guided hydrosalpinx aspiration during oocyte collection improves pregnancy outcome in IVF: a randomized controlled trial. Hum Reprod. 2008 May;23(5):1113-7. doi: 10.1093/humrep/den071. Epub 2008 Mar 13.</citation>
    <PMID>18343810</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2009</study_first_submitted>
  <study_first_submitted_qc>December 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2009</study_first_posted>
  <results_first_submitted>May 10, 2010</results_first_submitted>
  <results_first_submitted_qc>July 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2011</results_first_posted>
  <last_update_submitted>July 29, 2011</last_update_submitted>
  <last_update_submitted_qc>July 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Usama Fouda , MD, PhD</name_title>
    <organization>Cairo university.</organization>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Hydrosalpinx</keyword>
  <keyword>IVF-ET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was two arm prospective randomized controlled study including 110 fresh IVF- ETs from 110 patients , undertaken between October 2006 to May 2010 at the assisted conception unit of Ahmed Elgazzar hospital , Cairo , Egypt.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1: Hydrosalpinx Needle Aspiration</title>
          <description>After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .</description>
        </group>
        <group group_id="P2">
          <title>2. no Aspiration</title>
          <description>IVF-ET is done without prior aspiration of hydrosalpingeal fluid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55">October 2006</participants>
                <participants group_id="P2" count="55">October 2006</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54">May 2010</participants>
                <participants group_id="P2" count="53">May 2010</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>poor ovarian response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1: Hydrosalpinx Needle Aspiration</title>
          <description>After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .</description>
        </group>
        <group group_id="B2">
          <title>2. no Aspiration</title>
          <description>IVF-ET is done without prior aspiration of hydrosalpingeal fluid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.16" spread="3.6"/>
                    <measurement group_id="B2" value="29.38" spread="4.0"/>
                    <measurement group_id="B3" value="28.77" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Achieved Clinical Pregnancy in a Transfer Cycle</title>
        <description>The Number of Participants Who Achieved Clinical Pregnancy( presence of intrauterine gestational sac detected by transvaginal ultrasound
)in a transfer cycle</description>
        <time_frame>5 weeks after embryo transfer</time_frame>
        <population>Patients undergoing embryo transfer were included in final analysis</population>
        <group_list>
          <group group_id="O1">
            <title>1: Hydrosalpinx Needle Aspiration</title>
            <description>After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .</description>
          </group>
          <group group_id="O2">
            <title>2. no Aspiration</title>
            <description>IVF-ET is done without prior aspiration of hydrosalpingeal fluid</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Achieved Clinical Pregnancy in a Transfer Cycle</title>
          <description>The Number of Participants Who Achieved Clinical Pregnancy( presence of intrauterine gestational sac detected by transvaginal ultrasound
)in a transfer cycle</description>
          <population>Patients undergoing embryo transfer were included in final analysis</population>
          <units>participents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>. The aggregate result of 6 studies reporting the pregnancy rate of patients with ultrasound visible hydrosalpinx revealed that clinical pregnancy rate among the patients with ultrasound-visible hydrosalpinges was 12.6%. We assumed that the aspiration of hydrosalpinx could restore clinical pregnancy rate to that expected for patients with tubal factor of infertility but without hydrosalpinges (about 36.5% in our hospital)</non_inferiority_desc>
            <p_value>0.023</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Achieved Ongoing Pregnancy in a Transfer Cycle .</title>
        <description>The number of participants who Achieved Ongoing pregnancy (pregnancy for more than 18 weeks after embryo transfer) in a transfer cycle .</description>
        <time_frame>18 weeks after embryo transfer</time_frame>
        <population>Patients who underwent embryo transfer were included in the final analysis</population>
        <group_list>
          <group group_id="O1">
            <title>1: Hydrosalpinx Needle Aspiration</title>
            <description>After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .</description>
          </group>
          <group group_id="O2">
            <title>2. no Aspiration</title>
            <description>IVF-ET is done without prior aspiration of hydrosalpingeal fluid</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Achieved Ongoing Pregnancy in a Transfer Cycle .</title>
          <description>The number of participants who Achieved Ongoing pregnancy (pregnancy for more than 18 weeks after embryo transfer) in a transfer cycle .</description>
          <population>Patients who underwent embryo transfer were included in the final analysis</population>
          <units>participents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>October 2006 to May 2010</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1: Hydrosalpinx Needle Aspiration</title>
          <description>Aspiration of hydrosalpingeal fluid prior to IVF-ET</description>
        </group>
        <group group_id="E2">
          <title>2. no Aspiration</title>
          <description>IVF-ET without any prior intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Flaring of pelvic infection and peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Several patients refused to participate in the study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Usama M.Fouda, M.D, PhD</name_or_title>
      <organization>Cairo university</organization>
      <phone>+20123595106</phone>
      <email>umfrfouda@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

